First-of-Its-Kind Drainage Device Helps Limit Heart Failure Rehospitalizations

Why It Matters

The eLym system offers a novel, minimally invasive approach to decongestion, addressing a key driver of rehospitalization and mortality in heart‑failure patients who do not respond to standard diuretics.

Key Takeaways

• eLym device reduced thoracic duct pressure in 98% of patients
• Patients lost average 15 lb and maintained stable kidney function
• Six‑month freedom from HF hospitalization and death reached 82.5%
• Two serious adverse events: one death, one resolved hypotension
• WhiteSwell plans LYMPH‑HF pivotal trial across US, Canada, Europe, Israel

Pulse Analysis

Acute decompensated heart failure (ADHF) remains a costly clinical challenge, with fluid overload driving frequent readmissions and high mortality. Traditional diuretic therapy often falls short, especially in patients with renal dysfunction or diuretic resistance, prompting a search for alternative pathways to remove excess interstitial fluid. Leveraging the body’s lymphatic network, the eLym system creates a localized low‑pressure zone that actively extracts fluid via an endovenous micro‑axial pump, representing a paradigm shift from passive diuresis to active lymphatic drainage.

The DELTA‑HF trial’s single‑arm results are striking: 98% of participants achieved measurable thoracic duct pressure reductions, translating into near‑complete decongestion by discharge and an 82.5% six‑month event‑free survival—far better than the ~50% rehospitalization rate typical for diuretic‑non‑responders. Safety signals were modest, with only two serious procedure‑related events, underscoring the device’s feasibility in a high‑risk cohort. FDA breakthrough‑device designation further validates the technology’s potential to meet an unmet need and accelerate regulatory review.

Looking ahead, WhiteSwell’s LYMPH‑HF pivotal trial will compare eLym plus optimal diuretic therapy against diuretics alone across North America, Europe, and Israel. Success could reshape heart‑failure treatment algorithms, offering clinicians a tool to achieve rapid, sustained decongestion while preserving renal function. For investors, the combination of early efficacy data, regulatory momentum, and a sizable ADHF market—projected to exceed $30 billion in U.S. spending—positions the eLym system as a high‑impact, high‑return opportunity in cardiovascular innovation.